Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka, +12

The Lancet

Fitzroy StudyGastroenterologyClinical GastroenterologyUlcerative ColitisPhase 2 +2

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus, +25

The Lancet

InflammationChronic Inflammatory DiseasesFunctional Gastrointestinal DisorderPhase 2B/3Gastroenterology +3

Rapamycin decelerates cellular senescence

Zoya N. Demidenko, Elena I. Bukreeva, Valery A. Pospelov, +1

Cell Cycle

Progressive LossAgingCell DivisionCell RegulationLongevity +11

Global spatial risk assessment of sharks under the footprint of fisheries

Nuno Queiroz, Nicolas E. Humphries, Ana Couto, +147

Nature

Fishery AssessmentFishery ScienceGeographyFisheries ScienceSocial Sciences

Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice

Vladimir N. Anisimov, Mark A. Zabezhinski, Irina G. Popovich, +6

Cell Cycle

Feral Goat Eradications on Islands

Karl J. Campbell, C. Josh Donlan

Conservation Biology

Feral AnimalBiodiversityCaprineEngineeringFeral Goat Eradications +9

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg, +10

JAMA

Alien Insects: Threats and Implications for Conservation of Galápagos Islands

Charlotte E. Causton, Stewart B. Peck, Bradley J. Sinclair, +3

Annals of the Entomological Society of America

BiologyTerrestrial ArthropodBiodiversityInvasive SpecieEngineering +10

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler, +13

The Lancet

Rheumatoid DisorderRheumatologyAutoimmune DiseaseSpondyloarthritisOsteoarthritis +5

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen, +7

The Lancet Respiratory Medicine

FibrosisNovel Autotaxin InhibitorAllergyMedicinePulmonary Fibrosis +5